Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial

Overview of attention for article published in Breast Cancer Research, October 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

news: 1 news outlet

twitter: 2 X users

Citations

dimensions_citation: 46 Dimensions

Readers on

mendeley: 102 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 2,655 followers.

@RenataArakelian @PTarantinoMD @DrRBarroso https://t.co/ogzkvhDI2H

21 Jan 2022

Reply Repost Favourite

Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. https://t.co/tgyVGPHYTy

21 Oct 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.